GeNO 2012 News
12-18-2012 GeNO, LLC Announces Senior Management Appointments. Dasse Named President; Gellman Named Senior Vice President, Engineering.
11-13-2012 FDA Accepts GeNO, LLC Filing of New Drug Application for GeNOsylTM MVG-2000 Nitric Oxide Delivery System.
08-21-2012 GeNO, LLC Receives Four Additional Patents for Inhaled Nitric Oxide Delivery. 16 US Patents Protect Key Chemistry.
08-14-2012 FDA Grants Orphan Drug Designation to GeNO, LLC for use of Inhaled Nitric Oxide in Treatment of Persistant Pulmonary Hypertension of the Newborn (PPHN).
08-09-2012 GeNO, LLC Receives FDA Marketing Clearance for its Inhaled Nitric Oxide Drug Delivery Device. Apparatus is First GeNO Product Cleared by FDA.
07-31-2012 GeNO, LLC Receives Two Additional Patents for Inhaled Nitric Oxide Drug Delivery. Extends Patent Protection on Key Cartridge Chemistry to Year 2030.
04-19-2012 New Data Shows GeNO, LLC Nitric Oxide Delivery System Provided Nitric Oxide with Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation. Safety Results for Nitrosyl Could Signal Broader Testing in Cardio-Pulmonary Disease.
04-11-2012 New Data on GeNO, LLC Nitric Oxide Delivery System to be Presented at ISHLT Conference Next Week. First Human Data for Nitrosyl Examines Response to Inhaled Nitric Oxide in Cadiac Transplant Patients.
01-31-2012 GeNO, LLC Receives New Patent for Nitric Oxide Delivery Technology.
01-19-2012 GeNO, LLC Makes Significant Additions to Management Team to Increase Capability and Talent. Company Announces the Appointment of Four New Executives and Two Promotions.
Back to Current News